<SEC-DOCUMENT>0001140361-15-014468.txt : 20150406
<SEC-HEADER>0001140361-15-014468.hdr.sgml : 20150406
<ACCEPTANCE-DATETIME>20150406080527
ACCESSION NUMBER:		0001140361-15-014468
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150406
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150406
DATE AS OF CHANGE:		20150406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTORI THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		15752495

	BUSINESS ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584580900

	MAIL ADDRESS:	
		STREET 1:		3020 CALLAN ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>CYTORI THERAPEUTICS FORM 8K 040615
<TEXT>
<html>
<head>
    <title>form8k.htm</title>
    <!--Licensed to: Thomson Reuters-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<br>
<br>
<br>
<br>
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Form 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Report&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(Date of earliest event reported):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160; April 6, 2015</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-34375</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">33-0827593</font></div>
</td>
</tr><tr>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of Incorporation)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number)</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3020 Callan Road, San Diego, California 92121</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices, with zip code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(858) 458-0900</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">n/a</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="FONT-STYLE: italic; DISPLAY: inline"> see</font>&#160;&#160;General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="hangingindent"><!--EFPlaceholder--></a></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="&#61556;&#61537;&#61538;&#61490;"><!--efplaceholder--></a>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#9633;</font></div>
</td>
<td align="left" valign="top" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="pgbrk"><!--EFPlaceholder--></a><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="hdr"><!--EFPlaceholder--></a>Item 8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 6, 2015, Cytori Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing that its exclusive licensee, Lorem Vascular Pte. Ltd. (&#8220;Lorem&#8221;), was granted regulatory clearance for the Cytori Celution&#174; System by the State Food and Drug Administration of the People&#8217;s Republic of China (the &#8220;CFDA&#8221;).&#160; The CFDA clearance triggered certain purchasing obligations of Lorem for&#160;Cytori Celution Devices and Cytori Celution Consumable Sets.&#160; A copy of the press release is attached hereto as Exhibit 99.1.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d) Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Exhibit No.</font>&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="67%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Description</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated April 6, 2015</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CYTORI THERAPEUTICS, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;April 6, 2015</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: /s/ Tiago Girao</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tiago Girao</font></div>
</td>
</tr><tr>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">VP Finance and Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit Index</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</td>
</tr><tr>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="66%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cytori Therapeutics, Inc. Press Release, dated April 6, 2015</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>cytori_pr.htm
<DESCRIPTION>CYTORI PRESS RELEASE
<TEXT>
<html>
<head>
    <title>cytori_pr.htm</title>
    <!--Licensed to: Cytori-->
    <!--Document Created using EDGARizer 2020 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div><br>
&#160;</div>

<div><br>
<img src="cytori_logo.jpg" alt="LOGO"><br>
<br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Cytori and Lorem Vascular Receive Regulatory Clearance in China</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Cytori Receives China Opening Product Purchase Order from Licensee</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">April 06, 2015</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">SAN DIEGO, BEIJING - Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that its exclusive licensee, Lorem Vascular, has been granted regulatory clearance for the Cytori Celution&#174; System by the State Food and Drug Administration of the People&#8217;s Republic of China (CFDA).&#160;&#160;This regulatory clearance officially makes Cytori&#8217;s Celution System available in the largest healthcare market in the world and triggers a substantial 2015 product purchase order for Cytori from Lorem Vascular.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Cytori&#8217;s exclusive licensee in the region, Lorem Vascular, has worked closely with Cytori during the last year preparing for CFDA clearance and planning for commercial introduction of the Celution family of products in China. Today&#8217;s news marks the first time that Cytori&#8217;s Celution System has gained any level of access to the mainland Chinese healthcare market. Lorem Vascular will begin product launch of Celution in key hospitals in China immediately.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#8220;Our combined teams have spent the past year examining the delivery of healthcare in China and it is clear that diseases endemic is western countries are a rapidly growing burden on millions of citizens and already represent a heavy drain on resources of the healthcare system,&#8221; said David C. Oxley, Chief Executive Officer of Lorem Vascular. &#8220;With CFDA clearance, Lorem Vascular will now begin to consummate partnerships with key hospitals throughout China to address specific vascular and non-vascular applications using patients&#8217;&#160;own adipose derived regenerative cells, which have demonstrated clinical promise in studies around the world.&#8221;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">In November 2013, Cytori Therapeutics and Lorem Vascular entered into a 30-year exclusive licensing agreement to commercialize Cytori Celution System in China, Hong Kong, Malaysia, Singapore, and Australia. As part of that agreement, Lorem Vascular agreed to pay up to $500 million in fees to Cytori for a 30-year exclusive license for all indications, excluding alopecia, in the licensed territories following specific revenue milestones, as well as royalties of 30% on gross profits from Lorem&#8217;s operations in China, Malaysia and Hong Kong. Furthermore, following today&#8217;s news, Lorem Vascular placed an opening order of 23 Celution Devices and 1,100 Celution Consumable Sets, which is anticipated to be fulfilled throughout 2015. Following this opening order, Lorem Vascular has agreed to purchase annually a minimum of fifty (50) Celution Devices and fifty (50) Celution Consumable Sets for each of the Celution Devices for the next three years from CFDA clearance.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#8220;Lorem Vascular&#8217;s commitment to the Chinese market, along with today&#8217;s CFDA clearance and receipt of the opening order from Lorem Vascular is an important part of our 2015 plan and a key milestone for the year,&#8221; said Tiago Girao, Vice President of Finance and CFO of Cytori Therapeutics. &#8220;We intend to continue our full support of Lorem Vascular as it expands its commercial efforts throughout its territories in the years ahead.&#8221;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;<font style="FONT-WEIGHT: bold; DISPLAY: inline">About Cytori Therapeutics, Inc.</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Cytori Therapeutics is a late stage cell therapy company developing laboratory equipment and autologous cell therapies from adipose tissue to treat a variety of medical conditions.&#160;&#160;Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy&#8482; acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.&#160;&#160;As a result, Cytori Cell Therapy&#8482; may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori&#8217;s proprietary technologies and products.&#160;&#160;For more information: visit www.cytori.com.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">About Lorem Vascular</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Lorem Vascular Pte. Ltd. is a leader in the new field of regenerative medicine. Headquartered in Singapore, with offices in Australia, China, Hong Kong, and Malaysia, Lorem Vascular is transforming the quality of patient care by enabling hospitals and doctors to address a variety of major vascular and non-vascular diseases using patients&#8217; own cells.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Cytori Therapeutics, Inc.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Shawn Richardson, 1.858.875.5279</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">ir@cytori.com</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">or</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Lorem Vascular Pte Ltd</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">David Oxley, +61.488.303.060</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">doxley@loremvascular.com</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>

<br>
<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cytori_logo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 cytori_logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$D`
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`:.E'0'->`?MA?\`!0CP7^Q]I;)J32:UKTBYATJU8+)T
MR#(YX1?P)]J_/3XV_P#!?GXH-INH?V;X-\*:5I5Q$8P)UNI;E5;C<LH=$#8/
M]ROHLLX5S'&P]K2A:/=M*_I?5GQF=<>9/EE?ZM7J7J=HINWK;1?-GUM^V1^W
M3XJO_%\GPY^#MJ]_KTC>3<:C$OF^43QMC[#_`'OR_AW?'G[4?_!';X\>-?A?
MKGCWQ)XXT[5-4TVQEU&XT^\O[B6X\J-"\BA]ICWX!(%?0O\`P0F^*OA_]H7P
M[XL\1-8_9?%^FSQI>H[B78LWF8DC;`X.QATX^85T_P#P5J_;VMO`?PVU'X9^
M"6_MKQIXH1K"<6K;UM(VX=#CJ2.&']W<.OW>R$:^#Q:P6'@E*-N9M7[-OTL)
MU,-F.">.J3<HRORI-K7:UN]]&>!?\&Z_[4/CSQ=XR\5?#OQ!K&IZYH>F6)O;
M-;V=[A],=71617;)5#O^[TS7ZTK7Q-_P1E_X)_WO['OP8NM<\30^7XR\8*LM
MQ$X(>SA)W;#GD.QP6'^PO0[J^V`,CKWKQ<ZK4ZF+E*E:WEU?5GN9#1JTL'&%
M:]_/HNB'44#I17EGL!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`#=V*\U_:K^-"_`?X,:IKBX-YM^SV8(SF9E8@_@%)_"O2CTKP?\`X*#>
M`KGQW\#0ENI?[#?13R#_`&!G)_I^-=F6TZ<\5"%7X6U<\W-JE6&$J2H_%9V]
M3P+]AW]CJQ^.NL7GQ*^(4)URXGN&-O;W3%T9R=Q9L_>`SGW_`.^MU[_@N/X\
M\$_#S]A;4/!]]#ID.H>(KBVCTBT5$5H#%.DDDJH,;0$#)D?\]/[NZLOXZ?\`
M!1O0?^":W[*5I%=6)U;Q9J#.NC:?RL4I*@!Y,<[!CHOWO]GYBOS!^R3_`,$Y
M_BK_`,%5OB3'\9OC]JVHZ;X6O'$MCIZCRY[Z)6XCB3I##_M8^G?;]I!R>-_M
M#&SY:--^ZN]MDDOQ/SG%4(++WE674^>O55I2MMS+5MOK;;730Z'_`((P?!#Q
M1X6^!'B77=/U#^R&\?7$6F6#2-Y7F10>9NES_=+/M'^ZU?>?[./_``3W\(_!
M37V\3:E&OB#Q<[>9]MNEWK;-G.8P>X_O5YC^UG;:;\`M>\*>&?#-O!I>FVZV
M\5I90?+'`J%%`_*OL3P_=R7NA6,TW^MF@C=_]XJ":\7/LTJXFH\3'W54Z+>R
MLE=^A]7PSDM+`X6&#E[TJ:W\VVVTO5FE10.*,YKYD^M"BC-&:`"BC-!-`#0#
MGTHQC_\`50HKX=_X*H?\%'O'G[#_`(]\*Z3X3TOPG?6^N6$MW.^K6UQ,ZLC[
M0$\J:,8QZBM\+AJE>HJ5):LY<9C*>&INK5V7;4^XR*0+Q7F/['_QBU3X_P#[
M-'@_QEK,%C;ZIX@T];NYBLT=($<EAA`[,0O'=C7IY-95*;A)PENM/N-J-2-2
M"G'9BT445)H%%&:*`"BC-%`!1110`4444`%%%%`'(_%KXO>'?@?X)NO$7BC4
MK?2M)LUR\TK@;B>BJ.K,>P%?)7A+]MGQ7^W1XYFT?X?Z+<V/A*"7;/>SQ?-.
M@/WF)X4>W_H7RU\>?M(_&3Q%_P`%0OV_=,\!Z7J3Q>%8M3?3],@C),*6Z$F:
M[*Y&YV1&D_W=J]J_6;X5_"CPI^R_\*H='T>"UT?1])AW2S/C<^!S)(W&YC_]
M85]IB\KH9/AZ?MX\V(J*Z72*Z7ZM_J?F&5\08KB'&U?JLN3"4G9RZS?D]DDM
M?1GX/_\`!0GXR6]S_P`%7-/TGX@221^%O".J0Z;<A5+K!#&Y3S4&,XX\SZLU
M?LMXK_X**_!#X4^`K>;2?&WA?6;>&W1+*PT2\BNF*!`$0",D(`,=>@[5\#_M
M$?L"^$?^"K'[<.H:EIUSJF@,IQ>:G9*KI+%&>'DC88W;>.".=O\`>KZ5_9U_
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M6^.E_P"#@WXE'6C(W@OP.VF$Y\A?M0G^]_SU\W'W?]C_`.)KPO\`8N^"-U_P
M4+_;:6U\5WUS/#JTUQK_`(@N(VVR2Q*VYT0]MSND?^P&_P!FOUZ_X=S?`T^#
MO[#_`.%6^"Q9^7Y7F?8%^V8QC_CZ_P!?N_VM^:]^O2R_`<M*M!SFU=OM^)\W
MAZV8YBY5J$U""=DN_P"!PO["_P#P5+\$_MIWG]B_99O"?C2.,R?V3=3B9+M%
M&6:WEPOF8')4JK]]I4;JX;_@HQ_P4^\:?L-?&>QT*U\&:+K&B:OIR7]G>W%S
M+&[D,4EC(7C<I&?HZUZ/^R+_`,$N_AS^R'X]U?Q-HZ76LZQ>3N-.GU(B1M&M
MV_Y8Q?[?W@93\Y7`_O;N$_X+A?L]?\+;_9)7Q19P^9JWP_NA?A@N6:TEQ'<+
M^'[J0_\`7*O/H_498Z,8)\DM->C?8]&O]?CE\I3:52.MUV7_``#Z7_9J^-5G
M^T9\!/"GCBQC2&/Q%I\=U)"K;Q;3?=EBSQGRY%=,_P"S7F7_``4>_;@_X88^
M#^FZY9Z99ZQK6L:DEA9V=Q*8D9`C/+(2O.U54#_>D6OG[_@W^^/?_"3_``;\
M4?#NZF9KKPO?#4K%2W_+K<<.BC^ZDR,3_P!=Q7SO_P`%S?CC)\5?VN;/P?92
M27%GX%L8[3R4R^Z]N-LLN,=]A@7ZK6V&RI/,98>:]V-V_3I^AEB<XDLLCB(/
MWY))>O4^_O\`@FS^V-XH_;:^&>N>*M=\-Z;X=T^SU`6&GBUEDD-RRINE8[_X
M1O0#'^U7Y=_\%1/VMM2_:C_:#NK2_P!'L]+7P'=7VAV[6\CNUTB7+C>^[[K?
M)VK]@_V+?@)'^S3^S#X+\'&-4O-,T]'U#;SNO)/WL[9[_O68#VQ7Y[?\'#B[
M?C)\/??1K@_^1JZ,FJT?[2:IQT=^7?1+_,YL\HU_[,BZD]5;FT6K;_1G6?\`
M!(O_`(*0:UXT\4^!?@C)X;TN+2[#3;B)=3CN)#<$0Q22@E3QR1BOTPD98P69
M@JKR2>F*\+_X)EC_`(P+^%_R_P#,&CY_X$U8O_!6?XD7OPN_8-\=7NFS/;WF
MHPP:4DBG#*EQ.D<N/K$SBO,QD8U\=[.G'EO*V]];V;_X!ZN!E/#8'VM67-:-
M]K:6V_X)X#^UA_P7@T7X;>+;S0/AMH5MXMET^0Q3ZQ>7!33W<<'R43YI4_V]
MR+Z;A\U>8_#3_@X3\76VMQ?\)AX#\.WVFNV)#H\\]K-$I/WAYK2!B/[O&?5:
MY'_@BU^Q%X5_:;\4^*O$_C738]:TGPO]GM[+3YMWV:YN)=[,\@!&\(J+\AX/
MF\U]=?\`!1#_`()K?#'Q?^S1XJUOPSX/T'PGXD\+Z9/JMG<:/91V:S>0C2/#
M)'$%1]Z*5!(R#MYXKV:T,LP]98.<&WHG+S?S/#HU,UQ%%XR$TEJU'R7R_4^E
M/V?OV@_"_P"T[\,;#Q=X1U%;_2;[*L#\LUI*H&^&5,G9(F1D?0C*L"8?VK?C
M/=?L]?L[>+/&ME8PZC=>'+!KN.VF<I',00-I(Y[U^;/_``;Z?$Z\T[X[>,O!
M[7#?V;JNB?VJL3-QY]O/'%N`]2DYS_N?[-?>?_!3+_DPCXH_]@9__0EKQ\5E
M\:&.6'>L6U]S:/:P>93Q&7NNM))/[T?(7P\_X."$E\)>(KSQ3X+MX]6M5@71
MK#3KF3;?._F>8997!$:+MCZ!F^;I_=X73?\`@X2^(:>)UEN_`O@ZXT<M_P`>
ML$MS%<XST\XNR;O^V=>>_P#!'#]C_P`-_M5_'36KKQ?9#5-`\(V*71L&<K%=
MW$DFV(28()1520X_B^7/&Y6_4:?_`()_?!D>--!U^W^&_A72]4\,W"W5A+IU
MDMFJR#[K21Q;4E(;##>&PRJ:]?'?V;A*LJ+I\SMWT6FG7[SQ<O6:8RC&K&JH
MJ_S>NO0]$^%?C2\^(7PZT77;S1-2\-W6J64=U+I=_L^T6)89\M]I(S^OJ%.5
MKX;_`&6/^"R7B?\`:`_:RT'X=WG@O0]/LM6OKBT>\@NI7EC$<<CA@#QSY=?H
M2X_=D>@K\+/^":W_`"D]\&_]AB^_])[FO.RK"TJU*M.4?A5UOIN>IG&+K4*M
M"$)6YG9[:['[K`Y%%`X%%>&?1!1110!^$?C']D#X\?L%_M&+KWAWPQXBO)=!
MO7GTS6]+TU[ZTNHL,-S[`ZIN0L&CDVM7T)X8M_VNOV_+J'3?$5KJ'A/PN)1Y
M\EU8'2H64<$[&`DEY^M?JHT88<JI^M"K@_*%7Z5]UB..JM:*E4H0=6*LIM7:
M]%WOJ?E.#\*Z&%FZ='%5(T&[N"=D_)OJK:/2[[GE?[+/[+6A_LN>!DTO3&DO
M+R<*UY>RC#SN!UQ_"/:O50/E]Z4+D4-P:^*Q&(J5JCJU7>3W9^FX3"4L-2C0
MH+EC%62'$9%<#^TSX/G^(/[.?CWP_:JTEQKGAW4+")4^\SRVTD8`X/.6KOL\
M4TG*X-9PERR4NVIK4IJ<7'N?BC_P0Z^)&G>`/VY(;/4)5A_X2K1+K2+9GX4S
M&2&X5<^I^SX'OQ7[79S7Y"_\%(?^"4GC3X6?%?4?'GPMTJ^USPWJEX=0^Q:4
MKOJ.B7#-YC[(T&]H]_*-'\R=#MVJS>.M_P`%'?VF'TMO"/\`PFWBD2M'Y)@_
MLV)=2QG;Q-Y7V@-N_BW[J^OQV`CF4HXG#S6J2:>ZL?%X#,IY9&6%Q%-Z-V:Z
MW/W,TW7++5Y[A;.ZM[I[.8V]QY4@D\F10"4?!X<!AP>:A\9^$[#Q_P"$M4T/
M5(%N=-UBSELKJ(])894*.OXJ37YS_P#!&W]DOXT_#GXD7WC;Q1=:QX6\)ZM%
M(UWH^I9:Y\03./DE>)_FCVL=WFMAV^[]UFK]+LY%?-8S#QP]9PIR4K=5W/J,
M#B98JCSU(.-^C['X<_LG?$:3_@FA_P`%$M2L?$LUQ#I.CW%]H.K.L9W7-LW,
M,H`_A+I;R_[M/_X)U_#Z_P#VV?\`@HS9Z_K<9N([?4KCQAK&<E`4F\R-.>QN
M'B7']RO4?^"_WP2L_!OQW\+^-K5H8W\9:?);7L0(#M/9^6JS$9RV8YHD_P"V
M0KW3_@@3^S\W@OX":]\0+R$K>>,[W[+9,5_Y<[8E=P_WIC*#_P!<EKZ_$8N"
MP+QJ^.<5'YW:_P`_N/B\/@JCQZP3^"$G*WE9/_+[V??P'/TK\G_^#AW_`)+)
M\//^P-<?^CJ_6+I7P'_P6V_8S\4_M!>$/#'B_P`&Z7=:YJ'A47%MJ&G6L?F7
M<]O(49)(D'+^6Z'*+EOWG`X-?-Y'6A3QD95'9:K[T?4<049U<%*%-7>C^YH^
MA/\`@F7S^P5\+O\`L"I_Z$U>?_\`!;'0GUC_`()_>)9T5V_LV_L+IMOH;I(N
M?^_E?+/_``2)^.?QNT[X[^$_AKKTGB*S^'=E:WRBQO-#2)(2L4DBK]H:(2KB
M3H-_M7Z8?&3X5Z7\</A=KWA'6XWDTOQ!8R65QL.UT#C`=3_"ZG#+[@5IBJ;P
MF/52337-S:=F_P`R,'+ZYESIQ33Y>77NE;[CX!_X-X/%]E)X4^)7A\R*FH1W
MEGJ`C+<RQ,DD98#V9.?]Y:^U?VUO%ECX(_9%^)6I:A.EO:P^&[^,%FV[GD@>
M.-!_M-(Z*/=A7X__`!@_9*^-_P#P3=^,,NJZ"GB"&UM6=-/\3:+!(]M=0L>%
MEV[@A/\`%%+WZ;E^:L+Q?\?/VA/^"@7V/P[>7GBKQW"LP>.PT[3$BMO,7H\B
MV\:1_+G[\G2O8Q64QQ6*^MPJ+D=FW?:UO\NIXF%S>>%POU*=-\Z325M[GLG_
M``0&T2:__;+UN\4,L-CX6NBQV\9>YM5"_C\Q_P"`U^C'_!308_8*^*/_`&!G
M_P#0EK@_^"6/_!/^;]BOX7W]YX@:&;QQXK\M]2$3!X].C0$QVR,,AF!=B[CA
MC@?,$5F]`_X*/Z5=:U^PU\2K.SMY[RZN-'=8H((S))*=Z\!1DFO*QV*A7S*-
M2#NDXJ_>S1ZV7X.=#*Y0FK2:;MVNCXF_X-U_^1S^*G_7IIW_`*'<5^IG2OS&
M_P"#?KP-K?A'Q?\`$]M6T?5M+6XM=.$9N[.2W$I#W&<;@,XS7Z<9R166?R3Q
MLFO+\D;\.1<<#!/S_,'Y5OI7X5_\$U?^4GW@W_L,WW_I/<U^ZC\(:_$C_@G3
M\+O$VB_\%*?!U]>>'=>L[&/5[UFN)M/E2-0;>Y`)<J%[UU9')*AB$W]G_,Y.
M((MU\.TOM?JC]N:***^=/J`HHHH`****`"BBB@`HHHH`,9I-B_W1^5+10%D-
MVUY[^TI^T1X?_97^$M_XT\31ZA)H^FR11S+91"6;,D@1,*64?>8=Z]"DKY)_
MX+6?\H^/%O\`U^Z=_P"EL5=&"HQJUX4I;2:3./'UI4</*I#=*Y^</[?'[5-U
M_P`%(?VJ-#B\)Z9J4>FQK%HF@65SCS[F623F5D4LJF1W4=3\BK7[1_`KX3V7
MP+^#?AGP?I^UK7P[IT-BKA=OG,B`/(1ZNVYC[M7XJ_\`!(K_`)2&>`?^NMU_
MZ0M7[MQ=*]_B2*H>SPM/X4K_`-?UU/G>%FZZJ8RIK*3^[T_KH+GI28YJO#_K
M/PI'^ZOT'\C7RW=GUE^A:"X-*1FJDO\`J&^H_E3_`.-/I_A1S:LKH6",T@11
M_"/RJ$=OK42?Q?\``J(ZL'%7+1^8TI.[BH/XV_WA_2F?\MW^J_SH4M;>0F];
M%H+Z4N=U4Y/]9^?\Q3A_K!_NK_.J&6!_=HVJ#52?_7O_`+J_S-/?JWX_TI)@
LT6J"N:JO_K)/]W^M*_\`K%^M)LGF+"?=I%&#41^\OX_SJ+_EK_P(U11__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
